Comments
Lupin has received final approval from the US health regulator to market its antibacterial Nitrofurantoin capsules used for treating urinary tract infections.
According to a company statement, Lupin will market the Nitrofurantoin capsules in the strengths of 50 mg and 100 mg. The product is a generic version of Alvogen Malta Operations Ltd’s Macrodantin capsules in the same strengths.
As per IQVIA MAT April 2018 data, Nitrofurantoin capsules USP 50 mg and 100 mg had annual sales of around $27 million in the US.
Lupin shares were trading at Rs 899.15 per scrip on the BSE, down 0.22 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.